• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688075.SS
Share

Assure Tech Stocks

CN¥ 27.4Last Updated 22.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 545.05M

CN¥ 27.4
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China. It is also involved in POCT and plastic product manufacturing; online sales; pharmaceutical sales; and medical testing. In addition, the company offers drug of abuse, infectious disease, fertility, cardiac marker, tumor marker, allergen, and veterinary tests, as well as Biochemistry, chronic disease monitoring systems, and reader and analyzers. Further, it offers infectious disease, fertility, fecal occult blood, and vaginal pH tests. Assure Tech (Hangzhou) Co., Ltd. was founded in 2008 and is based in Hangzhou, China

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.07.2026 21:56

AMD will sell tens of billions worth of Anthropic AI servers and invest up to $5 billion in the company

22.07.2026 21:12

Google is expected to provide evidence that its AI spending is "reasonable." Should you buy shares before the earnings report?

22.07.2026 19:53

50% Jump: Revolut Begins Secondary Share Offering at a Valuation of $115 Billion

22.07.2026 18:52

Nvidia has found a new way to boost sales. Why might this be a "red flag"?

22.07.2026 18:35

Simply Good Food: Why Could the Protein Snack Maker's Stock Rise by 35%?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026